Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma (NCT01826448) | Daiichi Sankyo | 2013-11-05 |
Track Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor automatically
Every clearance here is in the API, with alerts when new ones post.